Disruption of differentiation in human cancer: AML shows the way
The DOI matches its Crossref record; 128 of the 128 references it cites were found in a registry or an index.
Abstract
Although much is understood about the ways in which transcription factors regulate various differentiation systems, and one of the hallmarks of many human cancers is a lack of cellular differentiation, relatively few reports have linked these two processes. Recent studies of acute myeloid leukaemia (AML), however, have indicated how disruption of transcription-factor function can disrupt normal cellular differentiation and lead to cancer. This model involves lineage-specific transcription factors, which are involved in normal haematopoietic differentiation. These factors are often targeted in AML--either by direct mutation or by interference from translocation proteins. Uncovering these underlying pathways will improve the diagnosis and treatment of AML, and provide a working model for other types of human cancer, including solid tumours.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Autoregulation may be a common feature of several transcriptional regulators to augment the relatively irreversible nature of differentiation processes in the hematopoietic system (60,61).”
From Potential Autoregulation of Transcription Factor PU.1 by an Upstream Regulatory Element (2005) · cites this paper as [60]
Citations
Cites
Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., et al. (1999) · Science · doi:10.1126/science.286.5439.531 · Cited by 11,516
Bonnet, D., & Dick, J. E. (1997) · Nature Medicine · doi:10.1038/nm0797-730 · Cited by 5,864 · cited 1×
“What is the role of lineage-specific transcription factors on stem cells, and how does this relate to AML? Although most of the blast cells from patients with AML clearly show a lineage- and stage-specific differentiation block, several studies support the idea that it is a disease that also involves the stem-cell com…”
BackgroundBennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1976) · British Journal of Haematology · doi:10.1111/j.1365-2141.1976.tb03563.x · Cited by 5,602
Lessons from hereditary colorectal cancer
Kinzler, K. W., & Vogelstein, B. (1996) · Cell · doi:10.1016/s0092-8674(00)81333-1 · Cited by 4,919
Purification and Characterization of Mouse Hematopoietic Stem Cells
Spangrude, G. J., Heimfeld, S., & Weissman, I. L. (1988) · Science · doi:10.1126/science.2898810 · Cited by 2,824
Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A., et al. (1998) · Blood · doi:10.1182/blood.v92.7.2322 · Cited by 2,655
A clonogenic common myeloid progenitor that gives rise to all myeloid lineages
Akashi, K., Traver, D., Miyamoto, T., & Weissman, I. L. (2000) · Nature · doi:10.1038/35004599 · Cited by 2,617
In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse
Schwarze, S. R., Ho, A., Vocero-Akbani, A., & Dowdy, S. F. (1999) · Science · doi:10.1126/science.285.5433.1569 · Cited by 2,416
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898 · cited 1×
“This could be applied either in treating bone marrow ex vivo with differentiation agents, followed by bone-marrow transplantation for re-introduction into the patient, or by local therapies, such as instillation into the lung by bronchoscop”
MethodOkuda, T., van Deursen, J., Hiebert, S. W., Grosveld, G., & Downing, J. R. (1996) · Cell · doi:10.1016/s0092-8674(00)80986-1 · Cited by 1,856 · cited 1×
“Whereas AML1 falls into the category of transcription factors that are involved in the development of haematopoietic cells from haemangioblasts (SCL is another), and disruption of AML1 results in loss of all definitive haematopoiesi”
Background
Research works printed but not linked: 2
- Zhang, P. et al. C/EBPα deficiency blocks granulocytic differentiation at the common myeloid progenitor stage in both adult and fetal liver myelopoiesis. Blood 98, 792a (2001).
- Duprez, E. A., Koch, H. & Tenen, D. G. C/EBPβ is an important target of PML–RARA during ATRA induced differentiation of APL cells. Blood 98, 833a (2001).
Cited by
Items 401–500 of 620
Abdel‐Azim, H., Sun, W., & Wu, L. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107403 · Cited by 16
“…(Collins et al, 1990; Gratas et al, 1993; Labrecque et al, 1998; Purton et al, 1999; Tsai et al, 1992; Tsai & Collins, 1993; Wang et al, 2002; Wang et al, 2006) at both transcription and cell cycle levels (Dimberg & Oberg, 2003; Friedman, 2002; Hu & Zuckerman, 2014; Tenen, 2003; Tenen et al, 1997).”
BackgroundInfluentialYao, J., Li, G., Cui, Z., Chen, P., Wang, J., Hu, Z., Zhang, L., & Wei, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.876076 · Cited by 15
“…a differentiation-related pathway, denotes the development and differentiation of the hematopoietic cells into various cell types of hematopoietic lineages such as erythrocytes, neutrophils, basophils, eosinophils, macrophages, and myeloid derived dendritic cells (Tenen, 2003; Zhang et al., 2017).”
BackgroundDifferentiation therapy in poor risk myeloid malignancies: Results of companion phase II studies
Norsworthy, K. J., Cho, E., Arora, J. K., Kowalski, J., Tsai, H., Warlick, E. D., Showel, M. M., Pratz, K. W., Sutherland, L., Gore, S. D., et al. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.09.003 · Cited by 15
“Given that a major attribute of cancer is a block in differentiation [3], many groups have attempted to harness differentiation strategies in diverse tumor types [4–8], the most successful example being all-trans retinoid acid (ATRA) and arsenic trioxide in APL [9–12].”
BackgroundMicroRNA-204 Potentiates the Sensitivity of Acute Myeloid Leukemia Cells to Arsenic Trioxide
Wang, Z., Fang, Z.-H., Lu, R.-Z., Zhao, H., Gong, T., Liu, D., Hong, L., Ma, J., & Zhang, M. (2019) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504019x15528367532612 · Cited by 14
Differential expression of Wnt13 isoforms during leukemic cell differentiation
Bunaciu, R. P., Tang, T., & Mao, C. D. (2008) · Oncology Reports · doi:10.3892/or.20.1.195 · Cited by 14
“Leukemic cells represent early hematopoietic progenitors at different stages fail to undergo terminal differentiation and apoptosis in situ (17).”
The Design of Selective and Non-selective Combination Therapy for Acute Promyelocytic Leukemia
Jing, Y., & Waxman, S. (2007) · Springer eBooks · doi:10.1007/978-3-540-34594-7_13 · Cited by 15
“The activity of C/EBPα (another important transcription factor of the C/EBP family required for normal granulocytic cell differentiation) has been found to be directly inhibited by binding to PML-RARα protein; therefore, PML-RARα proteolysis, in addition toovercoming transcriptional repression, also restores the activ…”
BackgroundVesely, D. L., Hoffman‐Liebermann, B., & Liebermann, D. A. (2006) · Oncogene · doi:10.1038/sj.onc.1210109 · Cited by 14
“Aberrations in the complex cytokine and transcription factor network that regulate hematopoiesis lead to hematological disorders (Liebermann et al., 1995; Moqattash et al., 1998; Zhu et al., 2002; Tenen, 2003; Rosmarin et al., 2005).”
BackgroundMishra, M., Singh, A., Thacker, G., Upadhyay, V., Sanyal, S., & Trivedi, A. K. (2023) · Cell Biology International · doi:10.1002/cbin.12017 · Cited by 13
“Multiple genetic defects involving either chromosomal translocations or mutations within oncogenes, lineage specific transcription factors, growth factor receptors, or abnormal signal transduction involving several different protein tyrosine kinases have been implicated in the development of myeloid leukemia (Tenen, 2…”
BackgroundSingle‐Cell Sequencing in Normal and Malignant Hematopoiesis
Wilson, N. K., & Göttgens, B. (2018) · HemaSphere · doi:10.1097/hs9.0000000000000034 · Cited by 13
Lin, T.-C., Jiang, S.-S., Chou, W., Hou, H., Lin, Y., Chang, C.-L., Hsu, C.-A., Tien, H., & Lin, L. (2011) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2011.05.002 · Cited by 13
“Acute myeloid leukemia (AML) is a hematologic malignant disease caused by uncontrolled proliferation and blocked differentiation of myeloid progenitors.(2) Hypermethylation of the CpG island associated with CCAAT/enhancer binding protein alpha (CEBPA), a gene that induces myeloid differentiation, results in silencing…”
BackgroundIdentification of an epithelial-specific enhancer regulating ESX expression
Neve, R. M., Parmar, H. R., Amend, C., Chen, C., Rizzino, A., & Benz, C. C. (2005) · Gene · doi:10.1016/j.gene.2005.10.001 · Cited by 12
“One hallmark of cancer is a loss of cell differentiation (Tenen, 2003).”
BackgroundPerrotti, D., & Harb, J. G. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.546914 · Cited by 12
“This is primarily dependent on inhibition of CCAAT/enhancer binding protein a (C/EBPa) [18], a transcription factor essential for granulocytic differentiation [90,91].”
Hematopoietic stem cells: cancer involvement and myeloid leukemia.
Xl, L., Xue, Y., Yj, Y., Cx, Z., Wang, Y., Yy, D., Yn, M., & Fu, J. (2015) · PubMed · Cited by 14
Inhibition of Ser/Thr phosphatase PPM1D induces neutrophil differentiation in HL-60 cells
Kamada, R., Kudoh, F., Yoshimura, F., Tanino, K., & Sakaguchi, K. (2017) · The Journal of Biochemistry · doi:10.1093/jb/mvx032 · Cited by 12
Cell differentiation inducers from a marine sponge Biemna sp.
Ueoka, R., Ise, Y., Okada, S., & Matsunaga, S. (2011) · Tetrahedron · doi:10.1016/j.tet.2011.04.098 · Cited by 12
Dimberg, A., Kårehed, K., Nilsson, K., & Oberg, F. G. (2006) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2006.01827.x · Cited by 13
FCHSD2 predicts response to chemotherapy in acute myeloid leukemia patients
Han, Y., Cui, J., Lu, Y., Sue, S., Arpaia, E., Mak, T. W., & Minden, M. D. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.06.011 · Cited by 12
Sarojam, S., Raveendran, S. K., Vijay, S., Sreedharan, J., Narayanan, G., & Sreedharan, H. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.9.3785 · Cited by 13
“Among the oncogenes that affects proliferation and cell death, the most important is those that are involved in the haematopoietic differentiation pathways (Tenen, 2003).”
BackgroundGranulocyte colony‐stimulating factor and leukemogenesis
de Figueiredo‐Pontes, L. L., Lima, R. S., & Rego, E. M. (2004) · Mediators of Inflammation · doi:10.1080/09511920410001713574 · Cited by 13
“Among the target genes of C/EBPa are G-CSF-R , IL-6 , E2F, c-MYC and defensin .(2) Inter-”
InfluentialThe microRNAs involved in human myeloid differentiation and myelogenous/myeloblastic leukemia
Wang, X., & Zhang, J. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00386.x · Cited by 11
“AMLs represent the clonal expansion of haematopoietic precursors blocked at different stages of erythroid, granulocytic, monocytic or megakaryocytic differentiation, thus altering the developmental programs of normal haematopoiesis [41].”
BackgroundKLF1/EKLF expression in acute leukemia is correlated with chromosomal abnormalities
Mansoor, A., Mansoor, M. O., Patel, J. L., Zhao, S., Natkunam, Y., & Bieker, J. J. (2020) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2020.102434 · Cited by 12
“Although chromosomal translocations leading to oncogene activation are a major contributor to leukemia [4, 5], hypomorphic [6, 7] or mutated [8] transcription factors can also play a role in leukemogenesis.”
BackgroundClinical significance of BECLIN1 and ATG5 expression in acute myeloid leukemia patients.
Lian, Y., Xie, Y., Hong, M., Zhu, Y., Zhao, H., Zhao, X., Zhu, H., Qiao, C., Li, J., & Qian, S. (2018) · PubMed · Cited by 11
Steidl, U. U., Schroeder, T. A., Steidl, C., Kobbe, G., Graef, T. T., Bork, S., Pechtel, S., Kliszewski, S., Kuendgen, A., Rohr, U. P., et al. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1349.013 · Cited by 11
Mashozhera, N. T., Reddy, C. S., Ranasinghe, Y. N., Natarajan, P., Reddy, U. K., & Hankins, G. R. (2025) · Molecules · doi:10.3390/molecules30102108 · Cited by 10
Pin1‐Mediated Prolyl Isomerization of Runx1 Affects PU.1 Expression in Pre‐Monocytes
Islam, R., Yoon, W., Woo, K. M., Baek, J., & Ryoo, H. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24462 · Cited by 11
“Mueller BU, Pabst T, Fos J, Petkovic V, Fey MF, Asou N, Buergi U, Tenen DG. 2006.”
InfluentialTang, Y., Tian, X., Xu, Z., Cai, J., Liu, H., Liu, N., Chen, Z., Chen, S., & Liu, F. (2021) · iScience · doi:10.1016/j.isci.2021.102410 · Cited by 10
“It has been suggested that leukemia often originates from aberrant differentiation blockage of hematopoietic progenitor cells, and unblocking such blockage may provide an efficient means of cure (Tenen, 2003).”
BackgroundNoncoding RNAs in Acute Myeloid Leukemia: From Key Regulators to Clinical Players
Fatica, A. (2012) · Scientifica · doi:10.6064/2012/925758 · Cited by 11
“Several miRNAs were found deregulated in APL, which is generally characterized by the t(15; 17) translocation [16].”
BackgroundInfluentialOn the path to understanding the nature of cancer
Abelev, G. I., & Eraiser, T. L. (2008) · Biochemistry (Moscow) · doi:10.1134/s0006297908050015 · Cited by 16
Ferrari‐Amorotti, G., Mariani, S. A., Novi, C., Cattelani, S., Pecorari, L., Corradini, F., Soliera, A. R., Manzotti, G., Fragliasso, V., Zhang, Y., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.128272 · Cited by 15
“While C/EBPα expression is finely regulated in normal hematopoietic cells, its expression/activity is consistently altered in myeloid leukemias (10), suggesting that genetic or functional inactivation of C/EBPα is an important event in leukemogenesis (10,11).”
BackgroundZhang, L., Wang, L., Xu, Y. X., Li, X., Chen, W., Zheng, Y., & Chen, G. (2006) · PubMed · Cited by 10
Dependence on Myb expression is attenuated in myeloid leukaemia with N-terminal CEBPA mutations
Volpe, G., Cauchy, P., Walton, D. S., Ward, C., Blakemore, D., Bayley, R., Clarke, M. L., Schmidt, L., Nerlov, C., García, P., et al. (2019) · Life Science Alliance · doi:10.26508/lsa.201800207 · Cited by 10
“(such as FLT3, RAS, and KIT) that lead to an aberrant proliferation capacity coupled with a disruption of terminal myeloid differentiation (Tenen, 2003; Rosenbauer & Tenen, 2007).”
Improving pharmacotherapy outcomes by pharmacogenomics: from expectation to reality?
Vizirianakis, I. S. (2005) · Pharmacogenomics · doi:10.2217/14622416.6.7.701 · Cited by 15
Ingram, R. (2005) · Nucleic Acids Research · doi:10.1093/nar/gni001 · Cited by 10
“For example, in leukaemia it is often the expression of one aberrant transcription factor that triggers a cascade of events starting with the recruitment of inappropriate chromatin modification activities to the cis-regulatory elements of specific genes and their subsequent deregulation (6).”
BackgroundTowards a pathogenesis-oriented therapy of acute myeloid leukemia
Hiddemann, W., Spiekermann, K., Buske, C., Feuring‐Buske, M., Braess, J., Haferlach, T., Schoch, C., Kern, W., Schnittger, S., Berdel, W. E., et al. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.07.004 · Cited by 10
“/ Critical Reviews in Oncology/Hematology 56 (2005) 235–245 237”
Approach to Acute Myeloid Leukemia with Increased Eosinophils and Basophils
Papadakis, S., Liapis, I., Papadhimitriou, S. I., Spanoudakis, E., Kotsianidis, Ι., & Liapis, K. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13030876 · Cited by 10
“The regulation of genes that drive eosinophil differentiation is controlled by a network of transcription factors including C/EBP α , C/EBP ε , GATA-1, GATA-2, FOG-1, and PU.1 [2,3].”
BackgroundEctopic expression of hC/EBPs in breast tumor cells induces apoptosis
Pal, P., Lochab, S., Kanaujiya, J. K., Sanyal, S., & Trivedi, A. K. (2009) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-009-0290-3 · Cited by 9
“Most of the available data suggest that C/EBP proteins function as transcriptional activators, but it is becoming increasingly apparent that they may even exert nontranscriptional effects [12, 23–26].”
BackgroundProteomic approaches in myeloid leukemia
Kanaujiya, J. K., Lochab, S., Pal, P., Christopeit, M., Singh, S. M., Sanyal, S., Behre, G., & Trivedi, A. K. (2011) · Electrophoresis · doi:10.1002/elps.201000428 · Cited by 9
Differential Analysis of Genetic, Epigenetic, and Cytogenetic Abnormalities in AML
Islam, M., Mohamed, Z., & Assenov, Y. (2017) · International Journal of Genomics · doi:10.1155/2017/2913648 · Cited by 9
“AML is a haematological disorder characterized by excessive proliferation of undifferentiated myeloid cells [1] in the bone marrow that infiltrate the liver, spleen, lymph node, and circulating blood [2].”
BackgroundMicrofluidic-Based Detection of AML-Specific Biomarkers Using the Example of Promyelocyte Leukemia
Emde, B., Kreher, H., Bäumer, N., Bäumer, S., Bouwes, D., & Tickenbrock, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238942 · Cited by 9
D'Angelo, V., Crisci, S., Casale, F., Addeo, R., Giuliano, M. G., Pota, E., Finsinger, P., Baldi, A., Rondelli, R., Abbruzzese, A., et al. (2009) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-28-39 · Cited by 9
Myeloid Leukemia, Myelodysplasia, and Myeloproliferative Disease in Children
Clark, J., Berman, J. N., & Look, A. T. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3431-5.00011-x · Cited by 10
Matsuo, H., Inagami, A., Ito, Y., Ito, N., Iyoda, S., Harata, Y., Higashitani, M., Shoji, K., Tanaka, M., Noura, M., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-05811-8 · Cited by 8
“A cute myeloid leukemia (AML) is a malignancy characterized by differentiation arrest and uncontrolled proliferation of hematopoietic precursor cells 1 .”
Chen, B., Wang, Z., Chen, Q., Zhang, Y., Wu, S., Zhang, Y., Li, A., Ouyang, W., Sima, L., Li, X., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117173 · Cited by 8
Enhancers and MYC interplay in hematopoiesis
Benetatos, L., Benetatou, A., & Vartholomatos, G. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01891-1 · Cited by 8
Ahmad, F., Rajput, S., Mandava, S., & Das, B. R. (2012) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2011.0317 · Cited by 8
“A mong the many oncogenes affecting proliferation and cell death, anomalies of the genes implicated in the closely regulated pathways of hematopoietic differentiation are key oncogenic events in acute myeloid leukemia (AML) (Tenen, 2003).”
Tumor Suppressor Genes in Myeloid Differentiation and Leukemogenesis
Britschgi, C., & Fey, M. F. (2009) · Future Oncology · doi:10.2217/14796694.5.2.245 · Cited by 8
Nie, Y., Su, L., Li, W., & Gao, S. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103379 · Cited by 10
RNA‐Mediated Gene Silencing in Hematopoietic Cells
Venturini, L., Eder, M., & Scherr, M. (2006) · BioMed Research International · doi:10.1155/jbb/2006/87340 · Cited by 10
Targeted Therapy with Imatinib: An Exception or a Rule?
Fabbro, D., Fendrich, G., Guez, V., Meyer, T., Furet, P., Mestan, J., Griffin, J. D., Manley, P. W., & Cowan‐Jacob, S. W. (2005) · Springer eBooks · doi:10.1007/3-540-26670-4_13 · Cited by 9
“The chronic phase of CML more closely resembles a myeloproliferative disorder rather than a leukemia, as during this phase of the disease the terminal differentiation of cells is normal (Tenen 2003).”
BackgroundOptimizing homeostatic cell renewal in hierarchical tissues
Alvarado, C., Fider, N. A., Wearing, H. J., & Komarova, N. L. (2018) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005967 · Cited by 8
The Molecular and Biological Function of MEF2D in Leukemia
Zhang, P., & Lu, R. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-62731-6_17 · Cited by 7
Single-cell multiomics reveals a gene regulatory circuit driving leukemia cell differentiation
Tian, X., Zhang, L., Tang, Y., Xiang, G., Wang, Z., Zhu, P., Yu, S., Jiang, F., Wang, S., Wang, J., et al. (2025) · Oncogene · doi:10.1038/s41388-025-03309-z · Cited by 7
“Leukemic blasts, due to its resemblance to developmentally arrested hematopoietic stem and progenitor cells (HSPCs) [2, 6, 7], have been targeted for maturation using normal lineage-determining transcription factors (TFs) with the hypothesis that leukemic blasts would differentiate along the…”
Fragliasso, V., Chiodo, Y., Ferrari‐Amorotti, G., Soliera, A. R., Manzotti, G., Cattelani, S., Candini, O., Grisendi, G., Vergalli, J., Mariani, S. A., et al. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24040 · Cited by 8
Liu, Y., Lei, P., Qiao, H., Sun, K., Lu, X., Bao, F., Yu, R., Lian, C., Li, Y., Chen, W., et al. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29192 · Cited by 7
“Acute myeloid leukemia (AML) is hematopoietic diseases with the accumulation of undifferentiated myeloid progenitor cells of myeloid cells in the bone marrow.(1,2) The patients under 60 years of age with AML in the long‐ term overall survival rate is 30% to 40%, and less than 10% for patients over the age of 60.”
BackgroundRubnitz, J. E., Razzouk, B. I., & Ribeiro, R. C. (2006) · Cambridge University Press eBooks · doi:10.1017/cbo9780511471001.020 · Cited by 8
Acute myeloid leukemia: leukemia stem cells write a prognostic signature
Gudgin, E. J., & Huntly, B. J. P. (2011) · Stem Cell Research & Therapy · doi:10.1186/scrt62 · Cited by 7
“Th ese studies have aided our understanding of the biology of AML as a disease characterized by transcriptional dysregulation [ 5 ].”
BackgroundGranulocytopoiesis and Monocytopoiesis
Khanna‐Gupta, A., & Berliner, N. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35762-3.00027-5 · Cited by 9
Survey and evaluation of mutations in the human KLF1 transcription unit
Gnanapragasam, M. N., Crispino, J. D., Ali, A. M., Weinberg, R. S., Hoffman, R., Raza, A., & Bieker, J. J. (2018) · Scientific Reports · doi:10.1038/s41598-018-24962-3 · Cited by 7
C/EBPα S248A mutation reduces granulocytic differentiation in human leukemic K562 cells
Singh, S. M., Trivedi, A. K., & Behre, G. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.02.090 · Cited by 7
A Network‐Driven Framework for Drug Response Precision Prediction of Acute Myeloid Leukemia
Wang, Y., Liu, R., Zhang, Y., Luo, X., Yu, C., Fang, S., Tan, N., & Tang, J. P. (2025) · Advanced Science · doi:10.1002/advs.202506447 · Cited by 8
Ranamukhaarachchi, D. G., Unger, E. R., Vernon, S. D., Lee, D., & Rajeevan, M. S. (2005) · Genomics · doi:10.1016/j.ygeno.2005.02.008 · Cited by 6
BmC/EBPZ gene is essential for the larval growth and development of silkworm, Bombyx mori
Mei, X., Huang, T., Chen, A., Liu, W., Li, J., Zhong, S., Shen, D., Qiao, P., & Zhao, Q. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2024.1298869 · Cited by 6
“C/EBPs typically has three structural components: a C-terminal leucine zipper domain, DNA-binding domain, and N-terminal transcriptional activation domain (Tenen, 2003).”
BackgroundcircAFF2 promotes the development of AML by binding to PML mRNA
Lei, Y., Zhang, X., Li, X., Xu, J., Yang, S., Li, F., Chen, W., Shan, Y., Ren, L., Zhuo, C., et al. (2025) · Oncogene · doi:10.1038/s41388-025-03299-y · Cited by 6
“PBMCs were then isolated using human whole blood mononuclear cell isolation solution (TBP science LDS1075) according to the protocol, and the resulting cells were treated with triploid red blood cell lysate (Solarbio life science R1010) for 5min to remove residual red blood cells.”
Discrimination of target by siRNA: designing of AML1–MTG8 fusion mRNA-specific siRNA sequences
Kasashima, K., Sakota, E., & Kozu, T. (2004) · Biochimie · doi:10.1016/j.biochi.2004.08.003 · Cited by 6
Taming Cell-to-Cell Heterogeneity in Acute Myeloid Leukaemia With Machine Learning
Sánchez-Corrales, Y. E., Pohle, R. V. C., Castellano, S., & Giustacchini, A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.666829 · Cited by 6
“LSCs lie at the top of AML cellular hierarchies, and carry an unlimited ability to self-renew as well as giving origin to a variety of more mature leukemic subsets (Tenen, 2003), each expressing characteristic patterns of cell surface markers.”
BackgroundRodenburg, M., Fischer, M., Engelmann, A., Harbers, S. O., Ziegler, M., Löhler, J., & Stocking, C. (2006) · Journal of Virology · doi:10.1128/jvi.01430-06 · Cited by 6
“cell lineage specificity of the leukemia (17, 30, 35, 53, 55).”
BackgroundWarenius, H. M., Kyritsi, L., Grierson, I., Howarth, A., Seabra, L., Jones, M., Thomas, C., Browning, P., & White, R. (2009) · PubMed · Cited by 6
Škorvaga, M., Nikitina, E., Kolenová, A., Puskacova, J., Leitnerová, M., Copáková, L., & Belyaev, I. Y. (2014) · Neoplasma · doi:10.4149/neo_2014_092 · Cited by 6
Piazza, F., & Semenzato, G. (2004) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.4.3.387 · Cited by 6
MicroRNA expression profiling in bone marrow: Implications in hematological malignancies
Costa, A., Osório, C., & Dias, S. (2009) · Biotechnology Journal · doi:10.1002/biot.200800194 · Cited by 6
“AML is characterized by clonal expansion of hematopoietic stem cells blocked at different stages of erythroid, granulocytic, monocytic or megakaryocytic differentiation [47].”
BackgroundExploiting the Inherent Metastasis of Leukemia to Improve Chemotherapeutic Approaches
Trendowski, M. R. (2014) · Cell & Developmental Biology · doi:10.4172/2168-9296.1000137 · Cited by 7
“However, when improper signaling or mutations occur within HSCs, the likelihood of leukemia pathogenesis is dramatically increased [58].”
BackgroundLeukemia and Leukemic Stem Cells
Jamieson, C. H. M., Passegue, E. A., & Weissman, I. L. (2004) · Research and perspectives in neurosciences · doi:10.1007/978-3-642-18883-1_12 · Cited by 6
Wu, S., Zhao, P., Hou, Y., He, L., Wang, Z., Yang, D., Chai, Y., Liu, J., Shen, Y., Li, A., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117492 · Cited by 5
Li, X., Qian, Q., Li, J., Zhang, L., Wang, L., Huang, D., Xu, Q., & Chen, W. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07926-0 · Cited by 5
“CELF1 expression and clinical data for AML were acquired from the TCGA database.”
Hematolymphoid neoplasms: World Health Organization versus rest of the world
Gujral, S. (2008) · Leukemia · doi:10.1038/leu.2008.327 · Cited by 5
Advancing haematopoietic stem and progenitor cell biology through single‐cell profiling
Hamey, F., Nestorowa, S., Wilson, N. K., & Göttgens, B. (2016) · FEBS Letters · doi:10.1002/1873-3468.12231 · Cited by 6
Grimwade, D. J. (2007) · Springer eBooks · doi:10.1007/978-0-387-33227-7_30 · Cited by 5
Insertional activation of myb by F-MuLV in SCID mice induces myeloid leukemia
Haeri, M., Li, Y., Li, Y., Li, Q., Spaner, D., & Ben‐David, Y. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.1943 · Cited by 5
“1 is an Ets transcription factor with multiple roles during normal hematopoiesis (29).”
BackgroundHenrich, S., Crossett, B., & Christopherson, R. I. (2007) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.200700055 · Cited by 5
Regulation of stem cell fate in hematopoietic development.
Leeanansaksiri, W., & Dechsukhum, C. (2006) · PubMed · Cited by 7
Transcriptional Regulation of Hematopoietic Stem Cells
Göttgens, B., & Green, A. R. (2004) · Elsevier eBooks · doi:10.1016/b978-012436643-5/50119-x · Cited by 5
Mo, Y., He, X., Shi, P., Ning, Y., Zhou, M., Cui, H., & Zhang, T. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1561477 · Cited by 4
Super-enhancer DNA methylation in cancer: the mechanism of action and therapeutic directions
Bi, Y., Zou, K., & Wang, K. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1610579 · Cited by 4
Ding, H.-X., Liu, Y., Lü, X., Liu, A., Xu, Q., & Yuan, Y. (2024) · Cancers · doi:10.3390/cancers16101796 · Cited by 4
Hematopoietic Stem Cell in Acute Myeloid Leukemia Development
Paulo, S., & Janz, F. D. L. (2012) · InTech eBooks · doi:10.5772/31998 · Cited by 4
“Thus, alteration of the transcriptional machinery appears to be a common mechanism leading to arrested differentiation (Pandolfi, 2001; Tenen, 2003).”
BackgroundTraditional Medicines Used in Differentiation Therapy of Myeloid Leukemia
Wang, R., Song, D., & Jing, A. Y. (2006) · 亚洲传统医药 · Cited by 4
Campana, D., & Pui, C. (2008) · Elsevier eBooks · doi:10.1016/b978-0-443-06694-8.50105-6 · Cited by 7
Hitting the target in IDH2 mutant AML
Wouters, B. J. (2017) · Blood · doi:10.1182/blood-2017-06-790394 · Cited by 4
“A block in myeloid differentiation is a hallmark ofAML.(3)Undifferentiated blast cells with enhanced self-renewal capabilities can accumulate in the bone marrow.”
BackgroundBarabino, S. M. L., Citterio, E., & Ronchi, A. E. (2021) · Cancers · doi:10.3390/cancers13153753 · Cited by 4
“Unsurprisingly, transcription factors (TFs) controlling the equilibrium between proliferation, differentiation, and apoptosis at the end point of the signaling pathways are often involved in preleukemic and leukemic transformation in MPN, MDS, and AML, as well as in other forms of cancer [45].”
BackgroundOptimal intercellular competition in senescence and cancer
Michaels, T. C. T., & Mahadevan, L. (2023) · Proceedings of the Royal Society A Mathematical Physical and Engineering Sciences · doi:10.1098/rspa.2023.0204 · Cited by 4
Leukemic stem cells show the way.
Bonnet, D. A. (2005) · PubMed · doi:10.5603/4593 · Cited by 4
Immunohistochemical analysis of differentiation in static and mixed prostate cancer spheroids
Hong, S., O’Connor, K. C., David, O., Giordano, C. L., LeBeau, H., & Clejan, S. (2003) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2003.tb00217.x · Cited by 4
Vizirianakis, I. S. (2010) · Wiley eBooks · doi:10.1002/9780470571224.pse295 · Cited by 4
Noura, M., Shoji, K., Nobe, M., Ishikawa, M., Tanaka, M., Okayama, A., Adachi, S., & Matsuo, H. (2025) · FEBS Open Bio · doi:10.1002/2211-5463.70104 · Cited by 3
Höckendorf, U., Dutta, S., Kloos, A., Runtsch, M. C., Zötsch, C., Vosberg, S., Wang, Y., Kienreich, S., Flasch, B., Malovan, G., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adu3313 · Cited by 4
Waliullah, A. S. M., Nguyen, T.-A., Dziegielewska, B., Zhang, J., Qiu, K., Tran, M. L., Nguyen, N., Wang, L., Pan, A., Nong, M. K., et al. (2026) · Blood · doi:10.1182/blood.2025030667 · Cited by 3
Self-citationSingle-cell atlas of AML reveals age-related gene regulatory networks in t(8;21) AML
Whittle, J. R. S., Meyer, S., Lacaud, G., Baker, S. M., & Iqbal, M. (2025) · eLife · doi:10.7554/elife.104978.3 · Cited by 5
Manoharan, S., & Perumal, E. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.108017 · Cited by 3
Kharas, M. G., & Daley, G. Q. (2010) · Genes & Cancer · doi:10.1177/1947601911407327 · Cited by 4
“Modifications of myeloid-specific transcription factors such as CCAAT/enhancer binding protein (CEBP) and PU1 are known contributors to leukemia.(106,107) Besides these transcription factors, RNA binding proteins can also regulate leukemia progression as shown in a recent study that identified the RNA binding protein…”
BackgroundClinical features and outcomes of hypocellular acute myeloid leukemia in adults
Song, I., Jo, D., Kim, H., Min, Y. H., Hong, D. S., Lee, W.-S., Shin, H., Lee, J., Park, J., & Kim, H. (2021) · Medicine · doi:10.1097/md.0000000000024185 · Cited by 3
Metadata
- Authors
- Tenen, D. G.
- Affiliations
- Harvard University (US)
- Corresponding author
- Tenen, Daniel G.
- ORCID
- Tenen, Daniel G.
- Venue
- Nature Reviews Cancer
- Published
- 2003-02
- Volume
- 3
- Issue
- 2
- Pages
- 89-101
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2050249118
- Cited by
- 612
- References
- 128
- Citations by year
- 2026: 7 · 2025: 20 · 2024: 16 · 2023: 15 · 2022: 6 · 2021: 23 · 2020: 20 · 2019: 16 · 2018: 17 · 2017: 22 · 2016: 20 · 2015: 18 · 2014: 25 · 2013: 33 · 2012: 27
- FWCI
- 7.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- acute myeloid leukemia, cell differentiation, transcription factors, lineage-specific transcription factors, hematopoietic differentiation, transcription factor mutations, solid tumors
- MeSH terms
- Cell Differentiation, Humans, Mutation, Neoplasms, Transcription Factors, Leukemia, Myeloid, Acute
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.